Liver‐Targeted Tolerogenic Vaccines: A Nano‐Membrane Coupled Approach for Autoimmune Disease Therapies
Advanced Materials · 2025-09 · 37 (35)
DOI: 10.1002/adma.202507743 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Materials, online erschienen am 16.06.2025. Verfasst von Xiaoyan Chen und 14 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-So…. Hauptthemen laut MEDLINE: Liver, Immune Tolerance, Autoimmune Diseases, Vaccines. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 71 Literaturangaben. Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China, Fundamental Research Funds for the Central Universities.
Abstract (Originalsprache)
The co‐delivery of auto‐antigens and immunomodulators for tolerance induction holds great potential in the treatment of autoimmune diseases. However, their efficacy in enriching antigens within target cells remains limited, and the use of immunomodulators poses a risk for systemic immunosuppression. Here, an apoptotic erythrocyte‐derived membrane is developed for the first time, demonstrating its strong abilities to target hepatic antigen‐presenting cells (APCs) and stimulate negative regulatory pathways. These apoptotic cell membranes are engineered onto the surface of intravenous lipid emulsions encapsulating disease‐associated antigens to generate a tolerogenic vaccine. This nano‐membrane coupled structure facilitates robust antigen loading, efficient liver delivery, and uptake by hepatic APCs; while, concurrently downregulating the expression of costimulatory molecules to promote immune tolerance. Intravenous administration of this tolerogenic vaccine induces multiple regulatory cell subpopulations, particularly IL‐10 secreting T cells, regulatory B cells, and memory regulatory T cells, collectively conferring effective protection against celiac disease, rheumatoid arthritis, and type 1 diabetes in murine models. More importantly, it is demonstrated that this vaccine induces antigen‐specific immune tolerance without compromising the normal immune responses to other antigens. The findings provide solid support for the application of this hepatic APCs‐targeted tolerogenic vaccine as a versatile and translatable platform for combating autoimmune diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial T…
ORCID-Profile: Xun Sun
Förderung
- National Natural Science Foundation of China
- National Key Research and Development Program of China
- Fundamental Research Funds for the Central Universities
- 111 project
- Higher Education Discipline Innovation Project
Zitieren
APA
Chen, X., Xie, Z., Wu, R., He, X., Qin, M., Wang, H., Bai, S., Chen, Z., He, C., Ou, Y., Zhao, Y., Xie, M., Zhang, Y., Du, G., & Sun, X. (2025). Liver‐Targeted Tolerogenic Vaccines: A Nano‐Membrane Coupled Approach for Autoimmune Disease Therapies. Advanced Materials, 37(35). https://doi.org/10.1002/adma.202507743
Vancouver
Chen X, Xie Z, Wu R, He X, Qin M, Wang H, et al. Liver‐Targeted Tolerogenic Vaccines: A Nano‐Membrane Coupled Approach for Autoimmune Disease Therapies. Advanced Materials. 2025;37(35). doi:10.1002/adma.202507743
BibTeX
@article{Chen2025,
author = {Chen, Xiaoyan and Xie, Zhiqiang and Wu, Ruinan and He, Xiyue and Qin, Ming and Wang, Hairui and Bai, Shuting and Chen, Zhengjun and He, Chunting and Ou, Yangsen and Zhao, Yuanhao and Xie, Mingxin and Zhang, Yongshun and Du, Guangsheng and Sun, Xun},
title = {Liver‐Targeted Tolerogenic Vaccines: A Nano‐Membrane Coupled Approach for Autoimmune Disease Therapies},
journal = {Advanced Materials},
year = {2025},
volume = {37},
number = {35},
doi = {10.1002/adma.202507743}
}
EUVIMED